These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1834126)

  • 1. Internalisation of the Bowman-Birk protease inhibitor by intestinal epithelial cells.
    Billings PC; Brandon DL; Habres JM
    Eur J Cancer; 1991; 27(7):903-8. PubMed ID: 1834126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential intracellular target proteins of the anticarcinogenic Bowman Birk protease inhibitor identified by affinity chromatography.
    Billings PC; St Clair W; Owen AJ; Kennedy AR
    Cancer Res; 1988 Apr; 48(7):1798-802. PubMed ID: 3280120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent.
    Kennedy AR
    Am J Clin Nutr; 1998 Dec; 68(6 Suppl):1406S-1412S. PubMed ID: 9848508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal epithelial cells contain a high molecular weight protease subject to inhibition by anticarcinogenic protease inhibitors.
    Habres JM; Billings PC
    Cancer Lett; 1992 Apr; 63(2):135-42. PubMed ID: 1562990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteases, protease inhibitors and radiation carcinogenesis.
    Kennedy AR
    Int J Radiat Biol; 2023; 99(6):882-890. PubMed ID: 34325613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-carcinogenic soyabean Bowman-Birk inhibitors survive faecal fermentation in their active form and do not affect the microbiota composition in vitro.
    Marín-Manzano MC; Ruiz R; Jiménez E; Rubio LA; Clemente A
    Br J Nutr; 2009 Apr; 101(7):967-71. PubMed ID: 19353764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A growth-regulated protease activity that is inhibited by the anticarcinogenic Bowman-Birk protease inhibitor.
    Billings PC; Habres JM
    Proc Natl Acad Sci U S A; 1992 Apr; 89(7):3120-4. PubMed ID: 1557421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of Bowman-Birk inhibitor and anti-Bowman-Birk inhibitor antibodies in sera of humans and animals treated with Bowman-Birk inhibitor concentrate.
    Wan XS; Serota DG; Ware JH; Crowell JA; Kennedy AR
    Nutr Cancer; 2002; 43(2):167-73. PubMed ID: 12588697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro digestibility of the cancer-preventive soy peptides lunasin and BBI.
    Park JH; Jeong HJ; Lumen BO
    J Agric Food Chem; 2007 Dec; 55(26):10703-6. PubMed ID: 18038984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soybean-derived Bowman-Birk inhibitor (BBI) blocks HIV entry into macrophages.
    Ma TC; Le Guo ; Zhou RH; Wang X; Liu JB; Li JL; Zhou Y; Hou W; Ho WZ
    Virology; 2018 Jan; 513():91-97. PubMed ID: 29040829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological significance of polymorphism in legume protease inhibitors from the Bowman-Birk family.
    Clementea A; Domoney C
    Curr Protein Pept Sci; 2006 Jun; 7(3):201-16. PubMed ID: 16787260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cytotoxic effect of Bowman-Birk isoinhibitors, IBB1 and IBBD2, from soybean (Glycine max) on HT29 human colorectal cancer cells is related to their intrinsic ability to inhibit serine proteases.
    Clemente A; Moreno FJ; Marín-Manzano Mdel C; Jiménez E; Domoney C
    Mol Nutr Food Res; 2010 Mar; 54(3):396-405. PubMed ID: 19885848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis.
    Kennedy AR; Billings PC; Wan XS; Newberne PM
    Nutr Cancer; 2002; 43(2):174-86. PubMed ID: 12588698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of the Bowman Birk protease inhibitor in mice following oral administration.
    Billings PC; St Clair WH; Maki PA; Kennedy AR
    Cancer Lett; 1992 Mar; 62(3):191-7. PubMed ID: 1596863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of 3-methylcholanthrene-induced cellular transformation by timed administration of the Bowman-Birk protease inhibitor.
    St Clair WH
    Carcinogenesis; 1991 May; 12(5):935-7. PubMed ID: 2029760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoconjugates of soybean Bowman-Birk protease inhibitor as targeted antitumor polymeric agents.
    Gladysheva IP; Moroz NA; Karmakova TA; Nemtsova ER; Yakubovskaya RI; Larionova NI
    J Drug Target; 2001; 9(5):303-16. PubMed ID: 11770701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1.
    Chen YW; Huang SC; Lin-Shiau SY; Lin JK
    Carcinogenesis; 2005 Jul; 26(7):1296-306. PubMed ID: 15746161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteases occurring in the cell membrane: a possible cell receptor for the Bowman-Birk type of protease inhibitors.
    Yavelow J; Caggana M; Beck KA
    Cancer Res; 1987 Mar; 47(6):1598-601. PubMed ID: 3545448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor.
    St Clair WH; Billings PC; Carew JA; Keller-McGandy C; Newberne P; Kennedy AR
    Cancer Res; 1990 Feb; 50(3):580-6. PubMed ID: 2297699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bowman-Birk inhibitor suppresses production of superoxide anion radicals in differentiated HL-60 cells.
    Ware JH; Wan XS; Kennedy AR
    Nutr Cancer; 1999; 33(2):174-7. PubMed ID: 10368813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.